Left-atrial Fibrosis in Persistent Atrial Fibrillation and Its Comorbidities

Condition(s) studied

Investigational drug(s) / intervention(s)

Screening on comorbidites: Patients with persistent atrial fibrillation that undergo ablation are screened for comorbidities

Study summary

Pulmonary vein isolation is an established intervention for atrial fibrillation. Patients with a paroxysmal atrial fibrillation have no or only few comorbidities and a good prognosis in respect to their atrial fibrillation. In contrast, patients with persistent atrial fibrillation often suffer from relevant comorbidities and recurrence of atrial fibrillation is common. Left-atrial fibrosis and its electrophysiological consequences are involved in the recurrence rate, but pathophysiological mechanisms are yet to be better characterized. The study investigates relevant comorbidities to elucidated their effect on atrial fibrosis and recurrence rates of atrial fibrillation. Furthermore, the investigators evaluate the prevalence of these comorbidities.

Eligibility

Primary outcome measure(s)

• quantification of area of left-atrial fibrosis in the heart — baseline
  During ablation elecrical maping of the left-atrium is done and percentage of left-atrial fibrosis (electrical tissue abnormalities) will be assessed
• Rate of recurrence of atrial fibrillation (yes/no) in the study group — 1 year after procedure (ablation)
  measure the recurrence of AF in follow-up with holter-ekgs

Trial sites (1)

Other trials for the same condition